Saluda Medical (ASX: SLD) — Why This Neuromodulation Company Is in the Spotlight

Sonal Goyal

07 September 2026 06:46 PM AEST

Saluda Medical (ASX: SLD) — Why This Neuromodulation Company Is in the Spotlight

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

• Saluda received FDA approval for its CAP24 surgical paddle lead, a key product milestone.

• U.S. surgical cases using Saluda's technology have commenced, marking the start of commercial rollout.

• FY26 results released in August 2026 provide the financial baseline for assessing commercialisation progress.

• SLD trades at $0.40 AUD, with US commercial uptake the primary near-term value driver.

Saluda Medical (ASX: SLD) trades at $0.40 per share. The medical technology company is at a pivotal stage in its commercial journey, having received important regulatory clearance in the United States and now working to build commercial momentum for its proprietary neuromodulation technology.

About the Company

Saluda Medical is an ASX-listed medical device company focused on neuromodulation — the use of electrical stimulation to modulate nervous system activity, particularly for the management of chronic pain. The company has developed a closed-loop spinal cord stimulation (SCS) platform that adapts in real time to patient movement and physiology, a capability that differentiates it from conventional open-loop SCS systems.

Neuromodulation is a growing field within medical technology, driven by increasing prevalence of chronic pain conditions and a desire to reduce opioid dependence. Saluda's technology aims to improve patient outcomes compared with existing therapies by delivering more precise and responsive stimulation.

Key Developments

The FDA approval of Saluda's CAP24 surgical paddle lead is a material milestone. The CAP24 is designed to provide more targeted stimulation delivery in the spinal cord, and its approval expands the commercial toolkit available to Saluda's U.S. physician customers. Regulatory clearance for new products is a critical step in any MedTech company's commercialisation journey and demonstrates the FDA's confidence in the device's safety and efficacy profile.

U.S. surgical cases using Saluda's technology have commenced, representing the tangible early stages of commercial adoption. While case volumes at this stage are modest, the commencement of surgeries is the precursor to the Volume ramp that will ultimately drive meaningful revenue. FY26 results provided investors with a baseline financial picture as the company transitions from development to commercialisation.

Key Catalysts to Watch

Growth in U.S. case volumes is the most important near-term metric. The rate at which hospitals and pain management centres adopt Saluda's platform will determine the Revenue trajectory and, ultimately, the path to profitability. Any announcement of new hospital or physician partnerships, or accelerating implant volumes, would be a significant positive catalyst.

Clinical data that demonstrates superior patient outcomes relative to existing neuromodulation therapies would strengthen the case for adoption and support reimbursement negotiations with U.S. insurance providers. Positive clinical evidence is essential in the medtech commercialisation process, particularly for premium-priced devices.

Risks to Consider

Medical device commercialisation in the United States is a complex, capital-intensive process. Building a sales force, achieving hospital formulary inclusion, and navigating reimbursement pathways all take time and resources. Saluda will need continued access to Capital during this phase, and any tightening of Equity markets could constrain its ability to fund commercialisation at the required pace.

The neuromodulation market is already served by well-capitalised incumbents including Medtronic, Abbott and Boston Scientific. These companies have established relationships with implanting physicians, extensive clinical data, and large sales organisations. Displacing or complementing them in the U.S. market is a significant commercial challenge for a relatively small ASX-listed company.

Reimbursement risk is also material. U.S. private insurers and Medicare/Medicaid may require substantial clinical evidence before covering Saluda's device, and any delays or unfavourable reimbursement decisions could slow commercial uptake.

Conclusion

Saluda Medical is at an exciting but inherently risky juncture — it has achieved meaningful regulatory milestones and begun commercial surgeries in the United States, yet the scale of commercial success remains to be demonstrated. For investors willing to accept the risk profile of a pre-profitability medical device company competing in a market dominated by large incumbents, SLD offers genuine upside if its platform achieves commercial traction. The FDA approval of CAP24 and the commencement of U.S. cases are encouraging signals, and the stock warrants watchlist attention from healthcare investors focused on medtech innovation.

Frequently Asked Questions (FAQs)

FAQs

Q: What is Saluda Medical's core technology?

A: Saluda has developed a closed-loop spinal cord stimulation platform that uses real-time sensing to adapt stimulation levels to patient movement and physiology, aiming to deliver more effective chronic pain management.

Q: What is the CAP24?

A: The CAP24 is a surgical paddle lead — a device implanted in the spine to deliver targeted electrical stimulation. It received FDA approval, expanding Saluda's product range for U.S. commercial use.

Q: Has Saluda generated revenue from U.S. sales?

A: U.S. surgical cases have commenced, marking the beginning of commercial activity. However, revenue from commercial operations remains at an early stage, and investors should expect a ramp-up period.

Q: Who are Saluda's main competitors?

A: The neuromodulation market is dominated by large medical device companies including Medtronic, Abbott and Boston Scientific, all of which have established SCS product lines and large commercial organisations in the U.S.

Q: What is the key milestone to watch for SLD investors?

A: Growth in U.S. implant case volumes, favourable reimbursement decisions from U.S. insurers, and updates on clinical evidence are the most important near-term milestones for assessing the commercial trajectory.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.